271 related articles for article (PubMed ID: 29226313)
21. Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.
Türk D; Hanke N; Wolf S; Frechen S; Eissing T; Wendl T; Schwab M; Lehr T
Clin Pharmacokinet; 2019 Dec; 58(12):1595-1607. PubMed ID: 31129789
[TBL] [Abstract][Full Text] [Related]
22. Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors.
Guo J; Zhou D; Li Y; Khanh BH
Biopharm Drug Dispos; 2015 Nov; 36(8):507-19. PubMed ID: 26081137
[TBL] [Abstract][Full Text] [Related]
23. Creation of Novel Sensitive Probe Substrate and Moderate Inhibitor Models for a Comprehensive Prediction of CYP2C8 Interactions for Tucatinib.
Templeton IE; Rowland-Yeo K; Jones HM; Endres CJ; Topletz-Erickson AR; Sun H; Lee AJ
Clin Pharmacol Ther; 2024 Feb; 115(2):299-308. PubMed ID: 37971208
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator.
Wang K; Yao X; Zhang M; Liu D; Gao Y; Sahasranaman S; Ou YC
CPT Pharmacometrics Syst Pharmacol; 2021 May; 10(5):441-454. PubMed ID: 33687157
[TBL] [Abstract][Full Text] [Related]
25. Results from Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Effect of Finerenone on the Pharmacokinetics of Comedications.
Heinig R; Gerisch M; Bairlein M; Nagelschmitz J; Loewen S
Eur J Drug Metab Pharmacokinet; 2020 Aug; 45(4):433-444. PubMed ID: 32125665
[TBL] [Abstract][Full Text] [Related]
26. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
[TBL] [Abstract][Full Text] [Related]
27. Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects.
Morcos PN; Guerini E; Parrott N; Dall G; Blotner S; Bogman K; Sturm C; Balas B; Martin-Facklam M; Phipps A
Clin Pharmacol Drug Dev; 2017 Jul; 6(4):388-397. PubMed ID: 27545320
[TBL] [Abstract][Full Text] [Related]
28. Application of physiologically based pharmacokinetic modelling for the prediction of drug-drug interactions involving anlotinib as a perpetrator of cytochrome P450 enzymes.
Jin Z; He Q; Zhu X; Zhu M; Wang Y; Wu XA; Lv Q; Xiang X
Basic Clin Pharmacol Toxicol; 2022 May; 130(5):592-605. PubMed ID: 35289081
[TBL] [Abstract][Full Text] [Related]
29. A comprehensive evaluation in clinic and physiologically-based pharmacokinetic modeling and simulation to confirm lack of cytochrome P450-mediated drug-drug interaction potential for pomotrelvir.
Yang Z; Rioux N; Vincent L; Jones HM; Cha D; Plummer A; Wilfret D; Kearney BP
CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1553-1564. PubMed ID: 37614073
[TBL] [Abstract][Full Text] [Related]
30. Clinical Exposure Boost Predictions by Integrating Cytochrome P450 3A4-Humanized Mouse Studies With PBPK Modeling.
Zhang J; Heimbach T; Scheer N; Barve A; Li W; Lin W; He H
J Pharm Sci; 2016 Apr; 105(4):1398-404. PubMed ID: 27019957
[TBL] [Abstract][Full Text] [Related]
31. Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens.
Moj D; Hanke N; Britz H; Frechen S; Kanacher T; Wendl T; Haefeli WE; Lehr T
AAPS J; 2017 Jan; 19(1):298-312. PubMed ID: 27822600
[TBL] [Abstract][Full Text] [Related]
32. Physiologically Based Absorption Modeling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Alectinib.
Parrott NJ; Yu LJ; Takano R; Nakamura M; Morcos PN
AAPS J; 2016 Nov; 18(6):1464-1474. PubMed ID: 27450228
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach.
Zhou D; Podoll T; Xu Y; Moorthy G; Vishwanathan K; Ware J; Slatter JG; Al-Huniti N
CPT Pharmacometrics Syst Pharmacol; 2019 Jul; 8(7):489-499. PubMed ID: 31044521
[TBL] [Abstract][Full Text] [Related]
34. Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats.
Giri P; Delvadia P; Ladani MK; Prajapati N; Gupta L; Patel N; Joshi V; Giri S; Jain MR; Srinivas NR; Patel PR
Eur J Pharm Sci; 2019 Mar; 130():107-113. PubMed ID: 30633968
[TBL] [Abstract][Full Text] [Related]
35. A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients.
Einolf HJ; Zhou J; Won C; Wang L; Rebello S
Drug Metab Dispos; 2017 Apr; 45(4):361-374. PubMed ID: 28122787
[TBL] [Abstract][Full Text] [Related]
36. Physiologically Based Pharmacokinetic Modeling of Palbociclib.
Yu Y; Loi CM; Hoffman J; Wang D
J Clin Pharmacol; 2017 Feb; 57(2):173-184. PubMed ID: 27402157
[TBL] [Abstract][Full Text] [Related]
37. Physiologically based pharmacokinetic modelling of oxycodone drug-drug interactions.
Rytkönen J; Ranta VP; Kokki M; Kokki H; Hautajärvi H; Rinne V; Heikkinen AT
Biopharm Drug Dispos; 2020 Feb; 41(1-2):72-88. PubMed ID: 31925778
[TBL] [Abstract][Full Text] [Related]
38. Predicting the effect of cytochrome P450 inhibitors on substrate drugs: analysis of physiologically based pharmacokinetic modeling submissions to the US Food and Drug Administration.
Wagner C; Pan Y; Hsu V; Grillo JA; Zhang L; Reynolds KS; Sinha V; Zhao P
Clin Pharmacokinet; 2015 Jan; 54(1):117-27. PubMed ID: 25260695
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the Potential for Drug-Drug Interactions with Inhaled Itraconazole Using Physiologically Based Pharmacokinetic Modelling, Based on Phase 1 Clinical Data.
Bergagnini-Kolev M; Kane K; Templeton IE; Curran AK
AAPS J; 2023 Jun; 25(4):62. PubMed ID: 37344751
[TBL] [Abstract][Full Text] [Related]
40. PBPK Modeling Strategy for Predicting Complex Drug Interactions of Letermovir as a Perpetrator in Support of Product Labeling.
Wang YH; Chen D; Hartmann G; Cho CR; Menzel K
Clin Pharmacol Ther; 2019 Feb; 105(2):515-523. PubMed ID: 29901213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
